Mikkael Sekeres, MD, 5/25/11

Video Author: Oncology Times editors and Creative Services staff, working with Concept2Motion Video Productions
Created on: 03.05.2012
Associated with: Oncology Times. 33(10):44, May 25, 2011

Mikkael Sekeres, MD, elaborates on his article “What We Can Still Learn from the Atomic Bomb”

All Videos
Most Viewed
Most Emailed

Creator: Sarah Maxwell
Duration: 4:22
Icro Meattini, MD, Consultant Clinical Oncologist at the University of Florence, discusses a subgroup analysis of a Phase III randomized study of women with early breast cancer, which he presented at the 2015 European Society for Radiotherapy & Oncology Forum in Barcelona.
Creator: Dan Keller
Duration: 5:41
Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses topics from a session on immunotherapy of melanoma at the International Meeting of the Society for Melanoma Research, and he summarizes presentations on the need for biomarkers for patient selection and as potential therapeutic targets themselves, the utility of immunotherapy plus radiation, and stimulation of antigen-presenting cells.
Creator: Sarah Maxwell
Duration: 1:44
Professor Hans Wildiers, MD, PhD, from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, explains why TDM-1 doubles progression-free survival in HER2-positive advanced refractory breast cancer.
Creator: Dan Keller
Duration: 5:39
Richard Furman, MD, discusses the Phase III trial of idelalisib, a first-in-class oral kinase inhibitor and highly selective inhibitor of the delta isoform of PI3 kinase, used in combination with rituximab. The data show better progression-free survival and objective response rates compared with rituximab plus placebo in CLL patients who had already received standard treatments and were not considered candidates for additional chemotherapy.
Creator: Dan Keller
Duration: 5:29
Smita Bhatia, MD, MPH, elaborates on the clinical implications of her research.
Creator: Peter Goodwin
Duration: 1:50
Changes in colorectal cancer mortality are found to be correlated with the level of screening uptake—providing a strong rationale for national bowel cancer screening programs, this researcher explains.
Creator: Dan Keller
Duration: 5:20
Jedd Wolchok, MD, elaborates on his presentation at the 10th International Meeting of the Society for Melanoma Research about the need for therapies for melanoma beyond current CTLA-4 blockade, findings on biomarkers for response, PD-L1 expression as a biomarker on tumor cells, and the potential for targeted combination treatments.
Creator: Peter Goodwin
Duration: 2:10
TARGIT-A investigators Jayant S. Vaidya, PhD, and Michael Baum, MB, ChB, FRCS, elaborate on their findings and the clinical implications.
Creator: Dan Keller
Duration: 6:51
Valentin Goede, MD, elaborates on the clinical implications of the “paradigm-changing” CLL11 Phase III study that found improved responses for patients with chronic lymphocytic leukemia receiving obinutuzumab-chlorambucil compared with those receiving rituximab-chlorambucil.
Creator: Sarah Maxwell
Duration: 2:39
Zoran Gatalica, MD, DSc, Executive Medical Director of Caris Life Sciences in Phoenix, Arizona, discusses his study of 1,400 patients with cancers of unknown primary site in whom 80 percent were found to have actionable molecular targets in a video interview at the European Cancer Congress.
Creator: Peter Goodwin
Duration: 2:18
Michele Maio, MD, PhD, Director of Medical Oncology & Immunotherapy at University Hosptial in Siena, Italy, and Keith Flaherty, MD, Director of the Termeer Center for Targeted Therapies at Massachusetts General Hospital, discuss the findings that they presented at the 2013 European Cancer Congress.
Creator: Peter Goodwin
Duration: 1:36
Kirstin De Bruijn, a doctoral student in the surgery department at Erasmus University Medical Center in Rotterdam, the Netherlands, discusses her findings about the links between diabetes and breast and colorectal cancers, which she presented at the 2013 European Cancer Congress.
Creator: Dan Keller
Duration: 1:35
Ian Kunkler, MRCP, FRCR, FRCP, FRSM, Professor and Consultant in Clinical Oncology at Edinburgh Cancer Center, talks about the top news in breast cancer from the meeting.
Creator: Dan Keller
Duration: 4:29
Clifford Hudis, MD, President of ASCO and Chief of the Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center, tells OT why CancerLinQ is going to change research and practice.
Creator: Dan Keller
Duration: 7:53
Lynn Schuchter, MD, the C. Willard Robinson Professor of Hematology-Oncology and Attending Physician at the University of Pennsylvania Hospital, discusses the top melanoma studies presented at the American Society of Clinical Oncology 2013 Annual Meeting.
Creator: Dan Keller
Duration: 12:22
Marcia S. Brose, MD, PhD, Assistant Professor of Otolaryngology and Head and Neck Surgery at Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, discusses the results of the DECISION trial.
Creator: Dan Keller
Duration: 3:40
Bruce Roth, MD, a specialist in genitourinary cancers, who is a Professor of Medicine at Siteman Cancer Center and Chair of the ASCO Cancer Communications Committee, new data presented at the 2013 ASCO Annual Meeting about determining optimal treatment for patients with sarcoma.
Creator: Dan Keller
Duration: 4:51
Roy Herbst, MD, PhD, Professor of Medicine and Pharmacology and Chief of Medical Oncology at Yale Cancer Center, discusses a promising new technique that overcomes the inability of T cells to attack cancer.
Creator: Dan Keller
Duration: 7:06
Guideline panel member Ann Partridge, MD, MPH, a member of the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, explains the key points.
Creator: Dan Keller
Duration: 4:58
Guideline lead author, Gary Lyman, MD, MPH, Professor of Medicine and Director of the Comparative Effectiveness and Outcomes Research Program in Oncology at Duke University School of Medicine, explains the key points.